Rani Therapeutics Holdings, Inc.

RANI

US7530181004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/01/2026 GMT			5-day change	1st Jan Change
1.420 ^USD	-4.70%		+2.90%	+5.19%

01-08	Rani Therapeutics Holdings, Inc. Initiates Phase 1 Study of RT-114 RaniPill®? for the Treatment of Obesity in Collaboration with ProGen	CI
12-21	Rani Therapeutics Holdings, Inc.(NasdaqGM:RANI) added to NASDAQ Biotechnology Index	CI

Rani Therapeutics Q3 net loss decreases, extends cash runway into 2028

Published on 11/06/2025 at 10:50 pm GMT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Rani Therapeutics Holdings, Inc.

01-08	Rani Therapeutics Holdings, Inc. Initiates Phase 1 Study of RT-114 RaniPill®? for the Treatment of Obesity in Collaboration with ProGen	CI
12-21	Rani Therapeutics Holdings, Inc.(NasdaqGM:RANI) added to NASDAQ Biotechnology Index	CI
11-06	Rani Therapeutics Q3 net loss decreases, extends cash runway into 2028	RE
11-06	Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
30/10/25	Rani Therapeutics Holdings, Inc. to Present Preclinical Data on Oral Delivery of Semaglutide Via the RaniPill®? Capsule at ObesityWeek®? 2025	CI
28/10/25	Rani Therapeutics Holdings Insider Bought Shares Worth $1,260,417, According to a Recent SEC Filing	MT
23/10/25	Rani Therapeutics announces the appointments of Abe Bassan and Vasudev Bailey, Ph.D. to board of directors	RE
23/10/25	Rani Therapeutics announces closing of oversubscribed $60.3 million private placement priced at-the-market under Nasdaq rules	RE
23/10/25	Rani Therapeutics Announces Board and Committees Changes	CI
22/10/25	Rani Therapeutics Holdings, Inc. announced that it has received $59.991765 million in funding from Samsara BioCapital LLC, RA Capital Management, L.P., Special Situations Funds, The Invus Group, LLC and other investor.	CI
22/10/25	Top Premarket Gainers	MT
20/10/25	Maxim Adjusts Rani Therapeutics Price Target to $10 From $5, Maintains Buy Rating	MT
20/10/25	Top Premarket Gainers	MT
20/10/25	Nikkei Soars as Investors Await New Premier, Trump Softens Tariff Stance	MT
20/10/25	Chugai, Rani Therapeutics Sign Licensing Deal to Advance Oral Biologic Formulation	MT
20/10/25	Chugai Pharmaceutical Co Ltd - enter into a license agreement for the development and commercialization of an oral formulation	RE
17/10/25	Top Midday Gainers	MT
17/10/25	Rani Therapeutics Enters Into Up to $1.09 Billion Collaboration, License Deal With Chugai Pharmaceutical -- Shares Rise Premarket	MT
17/10/25	Rani Therapeutics Announces Up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs	CI
17/10/25	Rani Therapeutics Shares Double After Deal With Chugai Pharma	DJ
17/10/25	Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma	RE
17/10/25	Rani Therapeutics announces up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics including rare disease and immunology programs and announces concurrent oversubscribed $60.3 million financing	RE
15/10/25	Rani Therapeutics Holdings, Inc. announced that it expects to receive $60.3 million in funding	CI
08/08/25	Rani Therapeutics Holdings files for mixed shelf offering of up to $200 million - SEC filing	RE
08/08/25	Rani Therapeutics Files $200 Million Mixed Shelf	MT

Chart Rani Therapeutics Holdings, Inc.

Duration

Period

RANI: Dynamic Chart

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.

Employees

106

Sector

Biotechnology & Medical Research

Calendar

03-24 - Q4 2025 Earnings Release (Projected)

More about the company